my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
07-28-2010: Bayer Schering Pharma AG, Germany, and Bayer Yakuhin, Ltd., Japan, announced that the Japanese regulatory authorities have granted approval for YAZ® (3 mg drospirenone/20 mcg ethinyl estradiol) for the treatment of dysmenorrhea.
YAZ is available in the US, Europe, Latin America and the region Asia Pacific. In the US and several other countries in various regions, it is approved as an oral contraceptive as well as for the treatment of the symptoms of Premenstrual Dysphoric Disorder (PMDD) and/or moderate acne vulgaris in women desiring oral contraception.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Bayer plans further expansion in Asia
The Bayer Group plans to further expand its production, distribution network and research activities in Asia and considerably increase its sales in the region in the coming years. “We aim to achieve a more than 60 percent increase in our sales in Asia by 2015,” Management Board Chairman Dr. ... more
After a good third quarter: Bayer confirms Group outlook
The Bayer Group achieved further sales growth and significantly increased earnings in the third quarter of 2011. “It was a good quarter for Bayer,” Management Board Chairman Dr. Marijn Dekkers said Thursday at the presentation of the interim report. He described the continuing growth moment ... more
Bayer remains “best in class” in sustainability
Bayer remains “best in class” in sustainability. This is demonstrated by the company's renewed inclusion in both the Dow Jones Sustainability World Index (DJSI World) and the Dow Jones Sustainability Europe Index (DJSI Europe). Bayer has been listed continuously in the DJSI World since its ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
BAYER INNOVATION GmbH (BIG) is part of Bayer’s innovation strategy and complements the innovation activities of the different subgroups in the fields of health care, nutrition and high-quality materials. Objective of BIG is to identify and develop new growth opportunities, thus preparing ... more
Bayer Pharmaceuticals Corporation
Outstanding specialty care takes constant innovation and dedication. These core values set Bayer HealthCare Pharmaceuticals apart and enable us to offer an industry-leading portfolio of products and support that healthcare providers and their patients require. Bayer HealthCare Pharmaceutic ... more
Partnering with community leaders and providing philanthropic support have long been a part of Bayer Corporation's culture. In 1953, Bayer created the first of three foundations that later all merged to become the Bayer Foundation. The Bayer Foundation is an endowed 501(c)(3) entity and is ... more
The Lead Discovery Center GmbH (LDC), based in Dortmund, Germany, a spin-off from Max-Planck-Innovation GmbH (MI) in Munich, with expertise in small molecule pharmaceutical drug discovery, has successfully licensed its first lead structure to a pharma partner. The agreement grants Bayer Sch ... more
EU regulators okay Qlaira for the treatment of heavy menstrual bleeding
Bayer Schering Pharma AG, Germany, has successfully concluded the European registration procedure for the introduction of Qlaira in the new indication treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The Netherlands served as Reference ... more
Bayer launches Betaferon in China
Bayer Schering Pharma announced the upcoming launch in China of Betaferon® (interferon beta-1b) for the treatment of relapsing-remitting forms of multiple sclerosis (MS). Betaferon is already approved in over 100 countries worldwide. With Betaferon and Gadovist®1.0, which was also recently ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2011 CHEMIE.DE Information Service GmbH, All rights reserved
